While reporting financial results for the third quarter on Wednesday, biopharmaceutical company Bristol-Myers Squibb Co. (BMY) raised its adjusted earnings guidance for the full-year 2021.
For fiscal 2021, the company now projects earnings in a range of $2.68 to $2.83 per share, down from the prior forecast of $2.77 to $2.97 per share, and also raised its adjusted earnings guidance to a range of $7.40 to $7.55 per share from the prior forecast range of $7.35 to $7.55 per share. Worldwide revenue is expected to increase in the high-single digits.
On average, 17 analysts polled by Thomson Reuters expect the company to report earnings of $7.47 per share on revenues growth of 9.2 percent to $46.44 billion for the year. Analysts' estimates typically exclude special items.
For the third quarter, the company reported net income attributable to Bristol-Myers Squibb of $1.55 billion or $0.69 per share, down from $1.87 billion or $0.82 per share in the prior-year quarter. Excluding items, adjusted net earnings per share for the quarter was $2.00, compared to last year's $1.63.
Bristol-Myers Squibb posted quarterly revenues of $11.62 billion, an increase of 10 percent from the same period a year ago.
Analysts expected quarterly earnings of $1.92 per share on revenues of $11.58 billion for the quarter.
U.S. revenues increased 12 percent to $7.3 billion and international revenues increased 8 percent to $4.3 billion from last year.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.